A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

@article{Angelico2007ARS,
  title={A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.},
  author={Mario Angelico and Alessandra Petrolati and Raffaella Lionetti and Ilaria Lenci and Patrizia Burra and Maria Francesca Donato and Manuela Merli and Mario Strazzabosco and Giuseppe Tisone},
  journal={Journal of hepatology},
  year={2007},
  volume={46 6},
  pages={1009-17}
}
BACKGROUND/AIMS We performed a randomized trial on pegylated interferon alfa-2a (Peg-IFNalpha) monotherapy vs Peg-IFNalpha and ribavirin in non-cirrhotic liver transplant recipients with recurrent hepatitis C. METHODS Forty-two patients transplanted for HCV-related cirrhosis 12-96 months earlier were randomized to Peg-IFNalpha monotherapy (180 microg weekly) or Peg-IFNalpha and ribavirin, up to the maximum tolerated dose, for 48 weeks. RESULTS Early virological response (EVR, i.e., HCV-RNA2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…